Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

43.30
-0.8600-1.95%
Post-market: 43.400.1000+0.23%19:30 EDT
Volume:3.35M
Turnover:145.42M
Market Cap:7.20B
PE:-12.44
High:44.19
Open:43.76
Low:42.79
Close:44.16
52wk High:86.74
52wk Low:42.63
Shares:166.18M
Float Shares:161.92M
Volume Ratio:1.36
T/O Rate:2.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:16.36
PE(LYR):-18.18

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
2 hours ago

How Investors May Respond To Ionis Stock After Phase 3 Kidney Disease Trial Win

Simply Wall St.
·
Oct 07

Movement Alert|Ionis Pharmaceuticals Overnight Rise 5.89%, Sefaxersen Phase 3 Trial Meets Primary Endpoint in IgA Nephropathy

Market Focus
·
Oct 07

Movement Alert|Ionis Pharmaceuticals Rises 5.15% in Regular Trading, Back-to-Back Phase 3 Wins Restore Market Confidence

Market Focus
·
Sep 29

Ionis Advances CHAMPION Phase 3 Trial in Angelman Syndrome, Raising Long‑Term Optionality for IONS Investors

TIPRANKS
·
Sep 29

Analysts Offer Insights on Healthcare Companies: NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 24

Ionis Pharmaceuticals Price Target Maintained with a $100.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 24

Belgium's Celyad H1 Net Loss Narrows on Lower Expenses

Reuters
·
Sep 24

France's Abionyx Pharma H1 Net Loss Widens as Financial Expenses Rise

Reuters
·
Sep 24

Movement Alert|Ionis Pharmaceuticals Falls 5.05% in Regular Trading, Multiple Pipeline Wins Fail to Offset Lingering Cardiovascular Setback Sentiment

Market Focus
·
Sep 23

Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 23

Movement Alert|Ionis Pharmaceuticals Rises 5.9% in Pre-Market Trading, Multiple Pipeline Catalysts as ALS and Kidney Disease Drugs Meet Phase 3 Endpoints

Market Focus
·
Sep 23

Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study

MT Newswires Live
·
Sep 23

Movement Alert|Ionis Pharmaceuticals Rises 5.9% Overnight, ALS Drug Ulefnersen Meets Primary Endpoint in Phase 3 Trial

Market Focus
·
Sep 23

Ionis Says Roche Phase 3 IMAgINATION Interim Data Show Sefaxersen Cuts Proteinuria in IgA Nephropathy

Reuters
·
Sep 23

Ionis Pharmaceuticals, - Sefaxersen Shows Statistically Significant Reduction in Proteinuria Versus Placebo at 37 Weeks

THOMSON REUTERS
·
Sep 23

Ionis Pharmaceuticals, - Imagination Study Meets Primary Endpoint with Sefaxersen at 37 Weeks

THOMSON REUTERS
·
Sep 23

Ionis Pharmaceuticals, - Sefaxersen Safety Profile Consistent with Previous Data, no New Safety Signals Identified

THOMSON REUTERS
·
Sep 23

Ionis Announces Positive Interim Data from Partner Roche’s Phase 3 Imagination Study in Iga Nephropathy (Igan)

THOMSON REUTERS
·
Sep 23

Ionis Pharmaceuticals, Inc.: Imagination Study Will Continue as a Blinded Study to Evaluate Change in Kidney Function over Two Years

THOMSON REUTERS
·
Sep 23